119 related articles for article (PubMed ID: 35963802)
1. Pharmacokinetics, Pharmacodynamics, and Tolerability of Olpasiran in Healthy Japanese and Non-Japanese Participants: Results from a Phase I, Single-dose, Open-label Study.
Sohn W; Winkle P; Neutel J; Wu Y; Jabari F; Terrio C; Varrieur T; Wang J; Hellawell J
Clin Ther; 2022 Sep; 44(9):1237-1247. PubMed ID: 35963802
[TBL] [Abstract][Full Text] [Related]
2. Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a).
Koren MJ; Moriarty PM; Baum SJ; Neutel J; Hernandez-Illas M; Weintraub HS; Florio M; Kassahun H; Melquist S; Varrieur T; Haldar SM; Sohn W; Wang H; Elliott-Davey M; Rock BM; Pei T; Homann O; Hellawell J; Watts GF
Nat Med; 2022 Jan; 28(1):96-103. PubMed ID: 35027752
[TBL] [Abstract][Full Text] [Related]
3. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652, a Reversible Fatty Acid Amide Hydrolase Inhibitor, in Healthy, Nonelderly, Japanese Men and Elderly, Japanese Men and Women: A Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Phase I Study.
Takizawa M; Hatta T; Iitsuka H; Katashima M; Sato Y; Kuroishi K; Nagashima H
Clin Ther; 2020 May; 42(5):906-923. PubMed ID: 32456804
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study.
Klaus B; Sachse R; Ammer N; Kelepouris N; Ostrow V
Growth Horm IGF Res; 2020 Jun; 52():101321. PubMed ID: 32325373
[TBL] [Abstract][Full Text] [Related]
5. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
Viney NJ; van Capelleveen JC; Geary RS; Xia S; Tami JA; Yu RZ; Marcovina SM; Hughes SG; Graham MJ; Crooke RM; Crooke ST; Witztum JL; Stroes ES; Tsimikas S
Lancet; 2016 Nov; 388(10057):2239-2253. PubMed ID: 27665230
[TBL] [Abstract][Full Text] [Related]
6. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects.
Willen D; Uhl W; Wolna P; Papasouliotis O; Yalkinoglu Ö
Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):27-40. PubMed ID: 31529406
[TBL] [Abstract][Full Text] [Related]
7. Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels.
Nissen SE; Wolski K; Balog C; Swerdlow DI; Scrimgeour AC; Rambaran C; Wilson RJ; Boyce M; Ray KK; Cho L; Watts GF; Koren M; Turner T; Stroes ES; Melgaard C; Campion GV
JAMA; 2022 May; 327(17):1679-1687. PubMed ID: 35368052
[TBL] [Abstract][Full Text] [Related]
8. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.
Tsimikas S; Viney NJ; Hughes SG; Singleton W; Graham MJ; Baker BF; Burkey JL; Yang Q; Marcovina SM; Geary RS; Crooke RM; Witztum JL
Lancet; 2015 Oct; 386(10002):1472-83. PubMed ID: 26210642
[TBL] [Abstract][Full Text] [Related]
9. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
10. Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE).
O'Donoghue ML; G López JA; Knusel B; Gencer B; Wang H; Wu Y; Kassahun H; Sabatine MS
Am Heart J; 2022 Sep; 251():61-69. PubMed ID: 35588897
[TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.
Enebo LB; Berthelsen KK; Kankam M; Lund MT; Rubino DM; Satylganova A; Lau DCW
Lancet; 2021 May; 397(10286):1736-1748. PubMed ID: 33894838
[TBL] [Abstract][Full Text] [Related]
12. JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B.
Gane E; Yuen MF; Kakuda TN; Ogawa T; Takahashi Y; Goeyvaerts N; Lonjon-Domanec I; Vaughan T; Schluep T; Hamilton J; Njumbe Ediage E; Hillewaert V; Snoeys J; Lenz O; Talloen W; Biermer M
Antivir Ther; 2022 Jun; 27(3):13596535221093856. PubMed ID: 35695169
[TBL] [Abstract][Full Text] [Related]
13. A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults.
Munjal S; Gautam A; Offman E; Brand-Schieber E; Allenby K; Fisher DM
Headache; 2016 Oct; 56(9):1455-1465. PubMed ID: 27613076
[TBL] [Abstract][Full Text] [Related]
14. A multi-purpose Japanese phase I study in the global development of vupanorsen: Randomized, placebo-controlled, single-ascending dose study in adults.
Fukuhara K; Furihata K; Matsuoka N; Itamura R; Ramos V; Hagi T; Kalluru H; Bramson C; Terra SG; Liu J
Clin Transl Sci; 2023 May; 16(5):886-897. PubMed ID: 37002654
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
[TBL] [Abstract][Full Text] [Related]
16. Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial.
Nicholls SJ; Nissen SE; Fleming C; Urva S; Suico J; Berg PH; Linnebjerg H; Ruotolo G; Turner PK; Michael LF
JAMA; 2023 Sep; 330(11):1042-1053. PubMed ID: 37638695
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of Single Doses of BI 425809 in Healthy Chinese and Japanese Subjects: A Randomized Study.
Tsuda Y; Ugai H; Wunderlich G; Shin JG
Clin Ther; 2019 May; 41(5):961-971. PubMed ID: 31005336
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, safety and tolerability of Bencycloquidium bromide, a novel selective muscarinic M1/M3 receptor antagonist, after single and multiple intranasal doses in healthy chinese subjects: an open-label, single-center, first-in-human study.
Sun L; Ding L; Wang Y; Zhou W; Yan Z; Sun W; Zhang H; Ou N; Chen X
Drugs R D; 2012 Mar; 12(1):17-28. PubMed ID: 22339483
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, Pharmacodynamics, and Tolerability of AZD5718, an Oral 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor, in Healthy Japanese Male Subjects.
Knöchel J; Nelander K; Heijer M; Lindstedt EL; Forsberg GB; Whatling C; Shimada H; Han DS; Gabrielsen A; Garkaviy P; Ericsson H
Clin Drug Investig; 2021 Oct; 41(10):895-905. PubMed ID: 34546534
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of pelacarsen in lowering Lp(a) in healthy Japanese subjects.
Karwatowska-Prokopczuk E; Lesogor A; Yan JH; Hurh E; Hoenlinger A; Margolskee A; Xia S; Tsimikas S
J Clin Lipidol; 2023; 17(1):181-188. PubMed ID: 36529659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
